Echinocandin resistance: An emerging clinical problem?

Maiken C. Arendrup, David S. Perlin

Research output: Contribution to journalReview article

140 Citations (Scopus)

Abstract

Purpose of review Echinocandin resistance in Candida is a great concern, as the echinocandin drugs are recommended as first-line therapy for patients with invasive candidiasis. Here, we review recent advances in our understanding of the epidemiology, underlying mechanisms, methods for detection and clinical implications. Recent findings Echinocandin resistance has emerged over the recent years. It has been found in most clinically relevant Candida spp., but is most common in C. glabrata with rates exceeding 10% at selected institutions. It is most commonly detected after 3-4 weeks of treatment and is associated with a dismal outcome. An extensive list of mutations in hot spot regions of the genes encoding the target has been characterized and associated with species and drug-specific loss of susceptibility. The updated antifungal susceptibility testing reference methods identify echinocandin-resistant isolates reliably, although the performance of commercial tests is somewhat more variable. Alternative technologies are being developed, including molecular detection and matrix-assisted laser desorption ionization-time of flight. Summary Echinocandin resistance is increasingly encountered and its occurrence makes susceptibility testing essential, particularly in patients with prior exposure. The further development of rapid and user-friendly commercially available susceptibility platforms is warranted. Antifungal stewardship is important in order to minimize unnecessary selection pressure.

Original languageEnglish (US)
Pages (from-to)484-492
Number of pages9
JournalCurrent Opinion in Infectious Diseases
Volume27
Issue number6
DOIs
StatePublished - Jan 1 2014

Fingerprint

Echinocandins
Candida
Invasive Candidiasis
Pharmaceutical Preparations
Epidemiology
Lasers
Technology
Pressure
Mutation
Therapeutics
Genes

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Infectious Diseases

Keywords

  • Candida
  • Echinocandins
  • Epidemiology
  • FKS hot spot mutation

Cite this

@article{dd30c94898664cb78c8c64eba0e6a656,
title = "Echinocandin resistance: An emerging clinical problem?",
abstract = "Purpose of review Echinocandin resistance in Candida is a great concern, as the echinocandin drugs are recommended as first-line therapy for patients with invasive candidiasis. Here, we review recent advances in our understanding of the epidemiology, underlying mechanisms, methods for detection and clinical implications. Recent findings Echinocandin resistance has emerged over the recent years. It has been found in most clinically relevant Candida spp., but is most common in C. glabrata with rates exceeding 10{\%} at selected institutions. It is most commonly detected after 3-4 weeks of treatment and is associated with a dismal outcome. An extensive list of mutations in hot spot regions of the genes encoding the target has been characterized and associated with species and drug-specific loss of susceptibility. The updated antifungal susceptibility testing reference methods identify echinocandin-resistant isolates reliably, although the performance of commercial tests is somewhat more variable. Alternative technologies are being developed, including molecular detection and matrix-assisted laser desorption ionization-time of flight. Summary Echinocandin resistance is increasingly encountered and its occurrence makes susceptibility testing essential, particularly in patients with prior exposure. The further development of rapid and user-friendly commercially available susceptibility platforms is warranted. Antifungal stewardship is important in order to minimize unnecessary selection pressure.",
keywords = "Candida, Echinocandins, Epidemiology, FKS hot spot mutation",
author = "Arendrup, {Maiken C.} and Perlin, {David S.}",
year = "2014",
month = "1",
day = "1",
doi = "10.1097/QCO.0000000000000111",
language = "English (US)",
volume = "27",
pages = "484--492",
journal = "Current Opinion in Infectious Diseases",
issn = "0951-7375",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

Echinocandin resistance : An emerging clinical problem? / Arendrup, Maiken C.; Perlin, David S.

In: Current Opinion in Infectious Diseases, Vol. 27, No. 6, 01.01.2014, p. 484-492.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Echinocandin resistance

T2 - An emerging clinical problem?

AU - Arendrup, Maiken C.

AU - Perlin, David S.

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Purpose of review Echinocandin resistance in Candida is a great concern, as the echinocandin drugs are recommended as first-line therapy for patients with invasive candidiasis. Here, we review recent advances in our understanding of the epidemiology, underlying mechanisms, methods for detection and clinical implications. Recent findings Echinocandin resistance has emerged over the recent years. It has been found in most clinically relevant Candida spp., but is most common in C. glabrata with rates exceeding 10% at selected institutions. It is most commonly detected after 3-4 weeks of treatment and is associated with a dismal outcome. An extensive list of mutations in hot spot regions of the genes encoding the target has been characterized and associated with species and drug-specific loss of susceptibility. The updated antifungal susceptibility testing reference methods identify echinocandin-resistant isolates reliably, although the performance of commercial tests is somewhat more variable. Alternative technologies are being developed, including molecular detection and matrix-assisted laser desorption ionization-time of flight. Summary Echinocandin resistance is increasingly encountered and its occurrence makes susceptibility testing essential, particularly in patients with prior exposure. The further development of rapid and user-friendly commercially available susceptibility platforms is warranted. Antifungal stewardship is important in order to minimize unnecessary selection pressure.

AB - Purpose of review Echinocandin resistance in Candida is a great concern, as the echinocandin drugs are recommended as first-line therapy for patients with invasive candidiasis. Here, we review recent advances in our understanding of the epidemiology, underlying mechanisms, methods for detection and clinical implications. Recent findings Echinocandin resistance has emerged over the recent years. It has been found in most clinically relevant Candida spp., but is most common in C. glabrata with rates exceeding 10% at selected institutions. It is most commonly detected after 3-4 weeks of treatment and is associated with a dismal outcome. An extensive list of mutations in hot spot regions of the genes encoding the target has been characterized and associated with species and drug-specific loss of susceptibility. The updated antifungal susceptibility testing reference methods identify echinocandin-resistant isolates reliably, although the performance of commercial tests is somewhat more variable. Alternative technologies are being developed, including molecular detection and matrix-assisted laser desorption ionization-time of flight. Summary Echinocandin resistance is increasingly encountered and its occurrence makes susceptibility testing essential, particularly in patients with prior exposure. The further development of rapid and user-friendly commercially available susceptibility platforms is warranted. Antifungal stewardship is important in order to minimize unnecessary selection pressure.

KW - Candida

KW - Echinocandins

KW - Epidemiology

KW - FKS hot spot mutation

UR - http://www.scopus.com/inward/record.url?scp=84927788542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927788542&partnerID=8YFLogxK

U2 - 10.1097/QCO.0000000000000111

DO - 10.1097/QCO.0000000000000111

M3 - Review article

C2 - 25304391

AN - SCOPUS:84927788542

VL - 27

SP - 484

EP - 492

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

SN - 0951-7375

IS - 6

ER -